

# Oxidative Stress and Mitochondrial Aldehyde Dehydrogenase Activity: A Comparison of Pentaerythritol Tetranitrate with Other Organic Nitrates

Andreas Daiber, Matthias Oelze, Meike Coldewey, Markus Bachschmid, Philip Wenzel, Karsten Sydow, Maria Wendt, Andrei L. Kleschyov, Dirk Stalleicken, Volker Ullrich, Alexander Mülsch, and Thomas Münzel

*Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik III, Angiologie und Kardiologie, Hamburg, Germany (A.D., M.O., M.C., P.W., K.S., M.W., A.L.K.); Universität Konstanz, Fachbereich Biologie, Konstanz, Germany (M.B., V.U.); ALPHARMA-ISIS GmbH & Co. KG, Langenfeld, Germany (D.S.); and Universitätsklinik Mainz, Medizinische Klinik II, Kardiologie, Mainz, Germany (A.M., T.M.)*

Received May 12, 2004; accepted August 24, 2004

## ABSTRACT

Mitochondrial aldehyde dehydrogenase (ALDH-2) was recently identified to be essential for the bioactivation of glyceryl trinitrate (GTN). Here we assessed whether other organic nitrates are bioactivated by a similar mechanism. The ALDH-2 inhibitor benomyl reduced the vasodilator potency, but not the efficacy, of GTN, pentaerythritol tetranitrate (PETN), and pentaerythritol trinitrate in phenylephrine-constricted rat aorta, whereas vasodilator responses to isosorbide dinitrate, isosorbide-5-mononitrate, pentaerythritol dinitrate, pentaerythritol mononitrate, and the endothelium-dependent vasodilator acetylcholine were not affected. Likewise, benomyl decreased GTN- and PETN-elicited phosphorylation of the cGMP-activated protein kinase substrate vasodilator-stimulated phosphoprotein (VASP) but not that elicited by other nitrates. The vasodilator potency of organic nitrates correlated with their potency to inhibit ALDH-2 dehydrogenase activity in mitochondria from rat heart and in-

crease mitochondrial superoxide formation, as detected by chemiluminescence. In contrast, mitochondrial ALDH-2 esterase activity was not affected by PETN and its metabolites, whereas it was inhibited by benomyl, GTN applied *in vitro* and *in vivo*, and some sulfhydryl oxidants. The bioactivation-related metabolism of GTN to glyceryl-1,2-dinitrate by isolated RAW macrophages was reduced by the ALDH-2 inhibitors benomyl and daidzin, as well as by GTN at concentrations  $>1 \mu\text{M}$ . We conclude that mitochondrial ALDH-2, specifically its esterase activity, is required for the bioactivation of the organic nitrates with high vasodilator potency, such as GTN and PETN, but not for the less potent nitrates. It is interesting that ALDH-2 esterase activity was inhibited by GTN only, not by the other nitrates tested. This difference might explain why GTN elicits mitochondrial superoxide formation and nitrate tolerance with the highest potency.

Organic nitrates such as nitroglycerin (glyceryl trinitrate; GTN) are widely used in the therapy of cardiovascular diseases such as stable and unstable angina (Abrams, 1995).

The present work was supported by Grant Mu1079/6-1 from the Deutsche Forschungsgemeinschaft (to V.U. and T.M.) as well as by a vascular biology grant from ALPHARMA-ISIS GmbH and Co. KG (to T.M.).

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.104.002600.

The anti-ischemic effects of organic nitrates are largely caused by venous and coronary artery dilation as well as the improvement of collateral blood flow, which all decrease myocardial oxygen consumption. Their use, however, is limited because of the rapid development of tolerance and cross-tolerance characterized by decreased sensitivity of the vasculature to the organic nitrates and to endothelium-dependent vasodilators, respectively (Mangione and Glasser, 1994; Warnholtz et al., 2002). It is thought that organic nitrates

**ABBREVIATIONS:** GTN, glyceryl trinitrate (nitroglycerin); NO, nitric oxide; ALDH-2, mitochondrial isoform of aldehyde dehydrogenase; ALDH, aldehyde dehydrogenase; sGC, soluble guanylyl cyclase; cGK-I, cGMP-dependent protein kinase I; ROS, reactive oxygen species; ISMN, isosorbide-5-mononitrate; ISDN, isosorbide dinitrate; PETN, pentaerythritol tetranitrate; PETriN, pentaerythritol trinitrate; PEDN, pentaerythritol dinitrate; PEMN, pentaerythritol mononitrate; DTNB, 5,5'-dithio-bis(2-nitrobenzoic acid); PEG-SOD, polyethylene-glycolated superoxide dismutase; GDN, glyceryl dinitrate; Sin-1, 3-morpholino sydnonimine; L-012, 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4-(2*H*,3*H*)dione sodium salt; LY83583, 6-aniloquinoline-5,8-quinone; VASP, vasodilator-stimulated phosphoprotein; P-VASP, phosphorylation state of VASP at serine239; PBS, phosphate-buffered saline; DTT, dithiothreitol; HPLC, high-performance liquid chromatography; CL, chemiluminescence; GC-MS, gas chromatography-mass spectrometry; ACh, acetylcholine; SNP, sodium nitroprusside; MV, mean value.

induce vasorelaxation by generating nitric oxide (NO) or a related *S*-nitrosothiol. Both enzymatic and nonenzymatic mechanisms of organic nitrate metabolism/bioactivation have been proposed. The list of candidate enzymes includes glutathione *S*-transferases (Lau et al., 1992), the cytochrome P450 system (Schroder, 1992), xanthine oxidoreductase (O'Byrne et al., 2000), and mitochondrial aldehyde dehydrogenase (ALDH-2) (Chen et al., 2002). The active metabolite(s) of GTN activates the target enzyme soluble guanylyl cyclase (sGC), increasing tissue levels of the second messenger cGMP. cGMP in turn activates a cGMP-dependent protein kinase (cGK-I), which mediates vasorelaxation by phosphorylating proteins that regulate intracellular  $Ca^{2+}$  levels (McDonald and Murad, 1995; Ignarro, 2002). An impairment of the NO signaling pathway by increased formation of reactive oxygen species (ROS) (Munzel et al., 1995) as well as an impaired biotransformation of organic nitrates may contribute to the development of tolerance and cross-tolerance. ALDH-2 has recently been identified as a GTN-metabolizing enzyme that is subjected to an oxidative mechanism-based inactivation (Chen et al., 2002; Sydow et al., 2004). These results provide the missing link between tolerance and cross-tolerance, the oxidative stress concept, and a decreased GTN biotransformation. However, the ALDH-2 concept was criticized in a recent study (DiFabio et al., 2003), because an appreciable number of Asiatic people possess a mutation of ALDH-2, which causes a loss of function, but yet show no signs of inherited tolerance to GTN. This apparent discrepancy may be explained if one recalls that this mutation affects the cofactor binding (Sladek, 2003), thereby probably leaving the ALDH-2 esterase and GTN reductase activity intact.

Several organic nitrates have been reported to induce tolerance. Examples include isosorbide-5-mononitrate (ISMN), isosorbide dinitrate (ISDN), and GTN (Abrams, 1987). In contrast, pentaerythritol tetranitrate (PETN) treatment has been described to cause less tolerance (Fink and Bassenge, 1997; Jurt et al., 2001) and induce less side effects, such as headaches (Pfaffenrath et al., 1998). In animal studies using dogs or rabbits, it was shown that chronic therapy with PETN causes no tolerance and less oxidative stress and has beneficial effects on the progression of atherosclerosis in hyperlipidemic rabbits (Mullenheim et al., 2001; Schwemmer and Bassenge, 2003). These effects may be explained by the property of PETN to induce ferritin and heme oxygenase-1, as shown in cultured endothelial cells (Oberle et al., 1999, 2003). Increased expression of ferritin could decrease the tissue levels of free iron and thereby reduce the formation of free radicals induced by a Fenton-type reaction. The protective effects of increased heme oxygenase-1 expression has been shown to be secondary to increased degradation of porphyrins to form bilirubin, a potent antioxidant (Yamaguchi et al., 1996), as well as carbon monoxide, which is a weak stimulator of soluble guanylyl cyclase and inhibits platelet aggregation (Brune and Ullrich, 1987).

With the present study, we sought to determine whether or not the biotransformation of GTN by ALDH-2 represents a common pathway of organic nitrate bioactivation and whether or not all organic nitrates induce oxidative stress during bioactivation, irrespective of their molecular structure. Therefore, ISMN, ISDN, GTN, and PETN and its metabolites PETriN, PEDN, and PEMN were tested for their

effects on mitochondrial ROS formation and ALDH-2 activity. Moreover, we assessed the effect of the ALDH-2 inhibitor benomyl on the vasodilator potency of these different organic nitrates in isolated, endothelium-intact rat aortic rings and observed a marked difference between PETN and GTN on one hand and the other nitrates on the other hand. Our present findings help to establish a unifying concept for the molecular mechanism underlying nitrate tolerance and cross-tolerance. Thus, in vivo GTN tolerance primarily impairs the high-potency pathway and is caused by oxidative inactivation of ALDH-2.

## Materials and Methods

**Materials.** GTN was purchased as an ethanolic stock solution (102 g/l) from UNIKEM (Copenhagen, Denmark). For organ chamber tension studies, GTN was used from a Nitrolingual infusion solution (1 mg/ml) from G. Pohl-Boskamp (Hohenlockstedt, Germany). PETN [with 80% (w/w) lactose], PETriN, PEDN, and PEMN were kindly donated by ALPHARMA-ISIS GmbH & Co. KG (Langenfeld, Germany). ISDN [with 60% (w/w) lactose] was obtained from Alexis Biochemicals (San Diego, CA), ISMN was obtained from Acros Organics (Fairlawn, NJ), and Ellman's reagent [5,5'-dithio-bis(2-nitrobenzoic acid); DTNB] and PEG-SOD were obtained from Sigma-Aldrich (Steinheim, Germany). PETN and PETriN are barely soluble in aqueous solutions and were used from stock solutions in dimethyl sulfoxide. For better comparison, all organic nitrates were used from stock solutions in dimethyl sulfoxide. 1,2- and 1,3-GDN were purchased from Cerilliant (Round Rock, TX). Peroxynitrite [oxoperoxonitrate (1-)] was synthesized according to the quenched-flow method as described previously (Saha et al., 1998). Benomyl [methyl-(butylcarbamoyle)-2-benzimidazole carbamate] was purchased from Chem Service, Inc. (West Chester, PA); daidzin (7-glucoside of 4',7-dihydroxy-isoflavone) was purchased from INDOFINE Chemical Company, Inc. (Hillsborough, NJ); 3-morpholino-sydnominine (Sin-1) was purchased from Calbiochem (San Diego, CA); and L-012 was purchased from Wako Pure Chemical Industries (Tokyo, Japan). All other chemicals were of analytical grade and obtained from Sigma-Aldrich, Fluka (Buchs, Switzerland), or Merck (Darmstadt, Germany).

**Animal Model, in Vivo Nitrate Tolerance.** Wistar rats treated with ethanol (sham) or nitroglycerin (3 days, 0.48  $\mu$ mol/h) were studied as described recently (Munzel et al., 2000). All animals were treated in accordance with the Declaration of Helsinki and with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and was granted by the Ethics Committee of the University Hospital Eppendorf.

**Isometric Tension Studies.** Vasodilator responses to organic nitrates and other vasodilators were assessed with isolated aortic rings mounted for isometric tension recordings in organ chambers, as described previously (Munzel et al., 1995). In selected experiments, vessels from rats were incubated with benomyl, an irreversible inhibitor of ALDH (10  $\mu$ M). In vitro tolerance development as a result of PETN treatment was assessed by ex vivo incubation of rat vessels with 100  $\mu$ M PETN for 30 min at 37°C in Krebs-HEPES buffer (5.78 g/l NaCl, 0.35 g/l KCl, 0.37 g/l  $CaCl_2$ , 0.30 g/l  $MgSO_4$ , 2.1 g/l  $NaHCO_3$ , 0.14 g/l  $K_2HPO_4$ , 5.21 g/l HEPES, and 2.0 g/l D-glucose) followed by a 1-h washout phase and subsequent recording of concentration-response curves with PETN. Cross-tolerance of PETN to GTN was assessed by the measurement of vasodilator responses to PETN with aortic rings pre-exposed to GTN in vitro (100  $\mu$ M for 30 min at 37°C) or in vivo (3 days of chronic infusion).

**Activity Assay for cGK-I and sGC.** Aortic segments (1 cm) from GTN- and sham-treated rats were frozen and homogenized in liquid nitrogen. Immunoblotting was performed with a mouse monoclonal antibody (16C2) specific for the phosphorylation state of VASP at

serine 239 (P-VASP), as described previously (Mulsch et al., 2001; Schulz et al., 2002). The effect of benomyl (10  $\mu$ M) on VASP phosphorylation was tested in the absence or presence of either acetylcholine (0.1  $\mu$ M), sodium nitroprusside (0.1  $\mu$ M), PETN (0.05  $\mu$ M), GTN (0.1  $\mu$ M), ISDN (10  $\mu$ M), or ISMN (1 mM). For PETN (0.05  $\mu$ M), GTN (0.1  $\mu$ M), and ISDN (100  $\mu$ M), the activation of sGC was determined by the formation of cGMP, which was measured by a nonradioactive assay kit from Amersham Biosciences Inc. (Freiburg, Germany). The effect of ALDH-2 inhibition on the organic nitrate-dependent stimulation of sGC was determined by the addition or exclusion of benomyl (10  $\mu$ M).

**ALDH-2 Dehydrogenase and Esterase Activity in Isolated Rat Heart Mitochondria.** The activity of ALDH in isolated mitochondria was determined by measuring the conversion of benzaldehyde to benzoic acid. Rat heart mitochondria were prepared according to a previously published method (Raha et al., 2000). Hearts from sham-treated rats were homogenized in HEPES buffer (50 mM HEPES, 70 mM sucrose, 220 mM mannitol, 1 mM EGTA, and 0.033 mM bovine serum albumin) and centrifuged at 1500g (10 min at 4°C) and 2000g for 5 min (the pellets were discarded). The supernatant was then centrifuged at 20,000g for 20 min, and the pellet was resuspended in 1 ml of HEPES buffer. The latter step was repeated, and the pellet was resuspended in 1 ml of Tris buffer (10 mM Tris, 340 mM sucrose, 100 mM KCl, and 1 mM EDTA). The mitochondrial fraction (approximately 5–10 mg/ml total protein) was kept on ice and diluted to approximately 1 mg/ml protein in 0.25 ml of PBS and preincubated for 10 min at room temperature in the presence or absence of the ALDH-2 inhibitors benomyl (1  $\mu$ M) or chloral hydrate (10  $\mu$ M) as well as peroxynitrite (500  $\mu$ M), hydrogen peroxide (10 mM), Ellman's reagent (5 mM), or organic nitrates (50–5000  $\mu$ M, except PETN, because of its limited solubility). For the measurement of ALDH-2 dehydrogenase activity, benzaldehyde (200  $\mu$ M) was added, and the samples were incubated for another 30 min at 37°C. ALDH activity in cytosolic fractions was measured in the 20,000g supernatant of heart homogenates (2 mg/ml total protein) upon incubation with 200  $\mu$ M NAD<sup>+</sup> and 200  $\mu$ M benzaldehyde for 30 min at 37°C. To determine the oxidative inactivation of ALDH-2 by Sin-1-derived peroxynitrite, isolated mitochondria (1.6 mg/ml in PBS) were lysed by sonication (to provide direct access for peroxynitrite and PEG-SOD) and incubated for 90 min at 37°C in the presence or absence of Sin-1 (0.1 or 1 mM), PEG-SOD (500 U/ml), or dithiothreitol (DTT) (1 mM). Then 1 mM NAD<sup>+</sup> and 0.5 mM benzaldehyde were added to the samples and further incubated for 30 min at room temperature. For the measurement of ALDH-2 esterase activity, methylbenzoate (1 mM) was added, and the samples were incubated for another 30 min at 37°C. Samples were sonicated and centrifuged at 20,000g (4°C) for 20 min, and the supernatant was purified by size-exclusion centrifugation through a Microcon YM-10 filter device from Millipore Corporation (Billerica, MA). Each sample (200  $\mu$ l) was subjected to HPLC analysis. The system consisted of an LKB pump, a Knauer UV/Vis detector, and a C18-Nucleosil 125  $\times$  4 100-3 reversed phase column from Macherey-Nagel (Düren, Germany). The mobile phase contained acetonitrile (35% v/v) in 50 mM citric acid buffer (65% v/v), pH 2.2. The substrate and its products were isocratically eluted at a flow rate of 0.8 ml/min, detected at 275 nm, and quantified using internal and external standards (benzoic acid, benzaldehyde, and methylbenzoate). The typical retention times were 4.2, 6.2, and 12.6 min, respectively.

**Measurement of Reactive Oxygen Species Production from Isolated Heart Mitochondria.** Mitochondrial stock solutions were diluted to final total protein concentrations of approximately 0.1 mg/ml in 0.5 ml of PBS. The dye L-012 (100  $\mu$ M) was used as described previously (Daiber et al., 2004) to quantify ROS after the addition of the complex II substrate succinate (final concentration, 4 mM). Chemiluminescence (CL) was monitored over 5 min using a Lumat LB9507 from Berthold Technologies (Bad Wildbad, Germany), and the signal at 5 min was expressed as counts per minute. ROS production was quantified in mitochondria from control rats

exposed to increasing concentrations of organic nitrates (50–5000  $\mu$ M, except PETN because of its limited solubility) in vitro.

**Measurement of GTN Biotransformation in RAW 264.7 Macrophages by GC-MS Analysis.** RAW 264.7 macrophages were cultured to confluence in 75-cm<sup>2</sup> flasks in Dulbecco's modified Eagle's medium from Biochrom (Berlin, Germany) supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, 4 mM glutamine, 1 mM pyruvate, and 1.5 mg/ml carbonate. Cells ( $50 \times 10^6$ ) were incubated in 10 ml of Hanks' buffered salt solution containing 10% fetal calf serum for 30 min with 1 to 10  $\mu$ M GTN. To determine the effect of ALDH-2 inhibition on GTN biotransformation, the cells were incubated with 1  $\mu$ M GTN in the presence of either benomyl (50  $\mu$ M) or daidzin (50  $\mu$ M). The culture medium was then discarded, and the cells were scraped from the culture bottle in 1 ml of AgNO<sub>3</sub> (20 mM) solution (Chen et al., 2002) and frozen at –20°C. After thawing, the cells were sonicated, and GTN as well as its metabolites 1,2- and 1,3-GDN were extracted with 2 ml of ethyl acetate (25% v/v)/pentane (75% v/v) as described previously (Gerardin et al., 1982). The organic phase was centrifuged for 10 min at 1600g and evaporated using a gentle nitrogen stream. The remaining sample was dissolved in acetonitrile. An aliquot of each sample (20  $\mu$ l) was injected into a GC-MS unit GC Star 3400 CX, MS Saturn 3 from Varian, Inc. (Palo Alto, CA). GTN and its metabolites were separated on an Optima delta 6 (0.25- $\mu$ m film, 30-m length, 0.25-mm diameter) gas chromatography column from Macherey-Nagel. The nitrates were detected at the mass of the nitro group ( $m/z = 46$ ) using the electron ionization mode. The temperatures were 150°C for the injector, 280°C for the transfer line, and 170°C for the ion trap. The temperature program for the column was 80°C for 4 min, 150°C at 5.75 min, 166°C at 13.75 min, and 300°C at 16.43 to 18.43 min. The helium flow was 2 ml/min, and typical retention times were 11.8 min for 1,2-GDN, 12.2 min for 1,3-GDN, and 13.2 min for GTN.

**Statistical Analysis.** Results are expressed as mean  $\pm$  S.E.M. One-way analysis of variance (Bonferroni or Dunn's method) was used for comparisons of vascular responses, L-012 chemiluminescence, cGK-I activity, cGMP responses, and ALDH-2 dehydrogenase and esterase activity. The EC<sub>50</sub> value for each experiment was obtained by log-transformation.

## Results

**Vasodilator Responses.** In endothelium-intact rat aorta, the vasodilator potency of the different organic nitrates roughly correlated with the number of –ONO<sub>2</sub> groups present in the molecule. PETN and GTN exhibited the highest potency (EC<sub>50</sub>, 8.5 and 22 nM, respectively; Fig. 1A and Table 1), followed by PETriN (EC<sub>50</sub>, 0.2  $\mu$ M), ISDN (EC<sub>50</sub>, 5  $\mu$ M), and ISMN (EC<sub>50</sub>, 170  $\mu$ M). The vasodilator potency of PEDN (EC<sub>50</sub>, 25  $\mu$ M) was lower than that of PETriN, and PEMN exhibited the lowest potency (EC<sub>50</sub>, 1 mM) (Fig. 1B and Table 1). PETN and GTN showed potency similar to the biological inducer of relaxation ACh (EC<sub>50</sub>, 35 nM).

The role of ALDH-2 in the bioactivation of the organic nitrates was assessed by the addition of benomyl (10  $\mu$ M) to the organ bath solution. Benomyl induced a marked rightward shift of the concentration-response curves of PETN, PETriN, and GTN (Fig. 1, A and B), indicating that ALDH-2 is involved in the bioactivation of these nitrates. In contrast, benomyl did not significantly affect the vasodilator potency of ISDN and ISMN (Fig. 1A, Table 1), thereby excluding the involvement of ALDH-2 in the bioactivation process of these two nitrates. Likewise, benomyl did not affect the vasodilator potency of the higher-denitrated PETN metabolites PEDN and PEMN (Fig. 1B). Therefore, bioactivation of PEDN and PEMN, similar to ISDN and ISMN, presumably involves


another, ALDH-2-independent pathway(s). The vasodilator response to the endothelium-dependent agonist ACh was not affected by benomyl (Fig. 1B and Table 1).

In additional experiments with higher concentrations of benomyl (100  $\mu\text{M}$ ), we ascertained that the concentration of

benomyl used (10  $\mu\text{M}$ ) was maximally efficacious with regard to ALDH-2 inhibition (data not shown). We thereby excluded the possibility that higher concentrations of organic nitrates surmounted inhibition by benomyl (as observed by the rightward shift of the concentration-response curve) because of the incomplete inhibition of ALDH-2. We cannot entirely exclude that the carbamoylating compound benomyl inhibits other targets in addition to ALDH-2, but Chen et al. (2002) showed that acetaldehyde, a natural substrate of ALDH-2, also inhibits GTN-dependent relaxation, probably by acting as a competitive inhibitor for GTN biotransformation (Chen et al., 2002). In a recent study, we made a similar observation with the specific ALDH-2 inhibitor daidzin, further supporting an important role for ALDH-2 in the bioactivation of GTN (Sydow et al., 2004).

To assess the influence of so-called in vitro tolerance on the vasodilator responsiveness of PETN, isolated rat aortic rings were exposed for 30 min to high concentrations of PETN (100  $\mu\text{M}$ ) or GTN (100  $\mu\text{M}$ ), followed by a 1-h washout period, before the assessment of vasodilator responses. Pretreatment with PETN caused a small but significant rightward shift of the PETN concentration-response curve ( $\text{EC}_{50}$  increased from 8.5 to 27 nM; Fig. 1C), indicating a weak degree of tolerance/tachyphylaxis. In contrast, in vitro treatment with high concentrations of GTN induced a larger rightward shift of the PETN vasodilator response curve ( $\text{EC}_{50}$  increased from 8.5 to 85 nM). This effect was even more pronounced when using aortic rings from in vivo GTN-treated rats ( $\text{EC}_{50}$  increased to 182 nM; Fig. 1C and Table 1). These results indicate that PETN induces a weak in vitro autotolerance (tachyphylaxis) and GTN induces a pronounced in vitro and in vivo cross-tolerance to PETN.

**Effect of ALDH-2 Inhibition on Activation of cGK-I and sGC by Organic Nitrates, SNP, and ACh.** cGK-I activity was assessed by the P-VASP detected by means of Western blotting. The 48-kDa protein VASP (on blots appearing as a 45- and 50-kDa double band) is a prominent and ubiquitous cGK-I substrate (Eigenthaler et al., 1993) and can be taken as a monitor for cGK-I activity in intact cells and tissues (Musch et al., 2001). ACh, SNP, PETN, GTN, ISDN, and ISMN caused a concentration-dependent increase in P-VASP levels (Fig. 2A). The bar graph shows summarized densitometric data of P-VASP levels from at least three independent experiments with aortae from different animals, demonstrating a significant stimulation of cGK-I activity by all vasodilators used. The stimulatory effect of the organic nitrates on cGK-I activity increased with an increasing number of  $-\text{ONO}_2$  groups (PETN > GTN > ISDN > ISMN); therefore, these results are in accordance with those obtained by isometric tension recordings. Coincubation with the ALDH-2 inhibitor benomyl (10  $\mu\text{M}$ ) significantly decreased the P-VASP levels in PETN- and GTN-stimulated vessels almost to control levels, whereas with all other organic nitrates, SNP and ACh VASP phosphorylation was not significantly altered (Fig. 2A). These results corroborate our vasodilator experiments showing that ALDH-2 specifically bioactivates PETN and GTN but not the lower-nitrated organic nitrates. The failure of benomyl to affect ACh- and SNP-dependent VASP phosphorylation proves that this ALDH-2 inhibitor does not interfere with the endothelium-dependent and -independent NO signaling pathway (i.e., NO synthase activity and sGC activation).



**Fig. 1.** Effect of ALDH-2 inhibition by benomyl on vasodilator activity of various organic nitrates in the rat aorta. A, dose-response curves of PETN (circles), GTN (triangles), ISDN (squares), and ISMN (diamonds) recorded in the presence (open symbols) or absence (filled symbols) of benomyl (10  $\mu\text{M}$ ). The data are the mean  $\pm$  S.E.M. of 6 to 12 independent experiments. B, dose-response of PETN (circles), ACh (inverted triangles), PETriN (squares), PEDN (triangles), and PEMN (diamonds) in the presence (open symbols) or absence (filled symbols) of benomyl (10  $\mu\text{M}$ ). The data are the mean  $\pm$  S.E.M. of 4 to 10 independent experiments. C, dose-response of PETN (circles), PETN after in vitro incubation with PETN (100  $\mu\text{M}$ ) for 30 min at 37°C (triangles), PETN after in vitro incubation with GTN (100  $\mu\text{M}$ ) for 30 min at 37°C (squares), and PETN after in vivo treatment with GTN for 3 days (inverted triangles). The data are the mean  $\pm$  S.E.M. of 4 to 10 independent experiments. For statistical analysis, see Table 1.

The activation of sGC by different organic nitrates was detected by measuring cGMP levels in rat aortic tissue with a cGMP-specific enzyme immunoassay. Treatment of isolated blood vessels with GTN (0.1  $\mu$ M) or PETN (0.05  $\mu$ M) caused a marked 2.5- to 5-fold increase in cGMP levels, which was almost reduced to control levels in the presence of benomyl (10  $\mu$ M; Fig. 2B). In contrast, the 5-fold increase in cGMP induced by ISDN (100  $\mu$ M) was slightly, though not significantly, reduced by the addition of benomyl (Fig. 2B). These results support our conclusion that GTN and PETN requires ALDH-2-dependent bioactivation to elicit a cGMP response, whereas ISDN-induced cGMP is largely independent of this bioactivation pathway. It should be noted that the high- and low-potency organic nitrates were employed at different con-

centrations to achieve similar pronounced effects with all organic nitrates tested.

#### Mitochondrial Reactive Oxygen Species Formation.

The formation of mitochondrial ROS was detected by a CL-based assay using the probe L-012. Isolated rat heart mitochondria were incubated in vitro with high concentrations of organic nitrates (50  $\mu$ M–5 mM) in the presence of L-012 (100  $\mu$ M), and CL was recorded for 5 min (see *Materials and Methods*). ISMN had no marked effect on ROS formation even with the highest concentration applied (5 mM), whereas ISDN at 5 mM showed a significant 2-fold increase in the CL signal (Fig. 3A). With GTN, a marked concentration-dependent increase in ROS formation was achieved, resulting in a near 7-fold increase above control at 5 mM GTN (Fig. 3A).

TABLE 1

EC<sub>50</sub> values for different organic nitrates and the endothelium-dependent vasodilator ACh in the presence and absence of the ALDH-2 inhibitor benomyl. Vessels were preincubated in the absence or presence of 10  $\mu$ M benomyl for 30 min.

Condition	EC <sub>50</sub> without Benomyl	EC <sub>50</sub> with Benomyl
GTN	-7.66 $\pm$ 0.08 (n = 19)	-6.56 $\pm$ 0.13*** (n = 10)
GTN upon GTN in vivo <sup>a</sup>	-6.54 $\pm$ 0.25 <sup>†††</sup> (n = 10)	-6.27 $\pm$ 0.08 (n = 4)
PETN	-8.07 $\pm$ 0.06 (n = 10)	-7.16 $\pm$ 0.06*** (n = 6)
PETN upon 100 $\mu$ M PETN <sup>b</sup>	-7.57 $\pm$ 0.13 <sup>#</sup> (n = 6)	N.D.
PETN upon 100 $\mu$ M GTN <sup>b</sup>	-7.07 $\pm$ 0.09 <sup>###</sup> (n = 5)	N.D.
PETN upon GTN in vivo <sup>a</sup>	-6.74 $\pm$ 0.05 <sup>###</sup> (n = 4)	N.D.
PETriN	-6.63 $\pm$ 0.11 (n = 6)	-5.76 $\pm$ 0.16* (n = 6)
ISDN	-5.29 $\pm$ 0.04 (n = 12)	-5.28 $\pm$ 0.23 (n = 7)
PEDN	-4.61 $\pm$ 0.13 (n = 6)	-4.66 $\pm$ 0.06 (n = 6)
ISMN	-3.77 $\pm$ 0.04 (n = 7)	-3.51 $\pm$ 0.14 (n = 6)
PEMN	-2.97 $\pm$ 0.18 (n = 4)	-3.10 $\pm$ 0.11 (n = 4)
ACh	-7.46 $\pm$ 0.07 (n = 55)	-7.47 $\pm$ 0.08 (n = 4)

N.D., not determined.


\*  $P < 0.05$ , \*\*\* $P < 0.001$ ; significance versus sample without benomyl treatment.

<sup>†††</sup>  $P < 0.001$ ; significance versus relaxation of control in response to GTN.

<sup>#</sup>  $P < 0.05$ , <sup>###</sup>  $P < 0.001$ ; significance versus relaxation of control in response to PETN.

<sup>a</sup> Dose-response curves recorded with tolerant vessels from rats that were treated for 3 days with GTN (0.48  $\mu$ mol/h/kg).

<sup>b</sup> Dose-response curves recorded with vessels that were treated in vitro with either 100  $\mu$ M PETN or GTN for 30 min at 37°C.



**Fig. 2.** Effects of various organic nitrates on NO/sGC downstream signaling in the presence and absence of the ALDH-2 inhibitor benomyl. A, activity of cGK-I in isolated rat aortic rings measured ex vivo by determining the P-VASP levels upon stimulation with different organic nitrates (PETN, GTN, ISDN, and ISMN) in the absence (black) or presence (gray) of the ALDH inhibitor benomyl (10  $\mu$ M). For comparison, this ratio was determined under nonstimulated (basal) conditions or in response to the endothelium-dependent vasodilator ACh and the endothelium-independent nitrovasodilator SNP in the presence or absence of benomyl. The data are the mean  $\pm$  S.E.M. of 3 to 9 independent experiments. The top part of the figure shows a typical blot for the determination of VASP phosphorylation. B, accumulation of cGMP in isolated rat aortic rings measured ex vivo in response to GTN (0.1  $\mu$ M), ISDN (100  $\mu$ M), or PETN (0.05  $\mu$ M) in the absence (black) or presence (gray) of benomyl (10  $\mu$ M). Each well contained 0.1  $\mu$ g of protein from aortic homogenates. The data are the mean  $\pm$  S.E.M. of 3 to 8 independent experiments. \*, significance versus control; #, significance versus sample without benomyl treatment.


PETN (500  $\mu\text{M}$ ) induced only a 3-fold increase in CL and thus was less efficacious than 500  $\mu\text{M}$  GTN (5-fold increase). With PETN and its metabolites, the capability to elicit mitochondrial ROS formation decreased with the loss of  $-\text{ONO}_2$  groups (PETN > PETriN > PEDN  $\geq$  PEMN) (Fig. 4A).

**Inhibition of ALDH-2 Dehydrogenase Activity by Organic Nitrates.** The activity of ALDH-2 in isolated rat heart mitochondria was measured by the conversion of benzaldehyde to benzoic acid, as described previously (Sydow et al., 2004). ISMN, even at a high concentration (5 mM), did not alter the activity of ALDH-2 (Fig. 3B). ISDN induced a clear concentration-dependent decrease in ALDH-2 activity, a maximum of 50% at 5 mM, whereas GTN, at intermediate concentrations (500  $\mu\text{M}$ ), already completely inhibited the enzyme (the remaining signal corresponds to background activity) (Fig. 3B). In contrast, PETN was a less potent inhibitor of ALDH-2 activity (Fig. 3B). ALDH-2 activity was not significantly affected by PEDN and PEMN treatment (Fig. 4B). We were surprised to find that PETriN and PETN seemed to be equally effective in inhibiting ALDH-2 dehydrogenase activity. In a comparison of Figs. 3, A and B, and 4, A and B, it becomes evident that the potency of the different organic nitrates to inhibit ALDH-2 dehydrogenase activity is mirrored by their potency to elicit mitochondrial ROS formation. These findings therefore demonstrate a direct correlation between organic nitrate-dependent ROS formation and ALDH-2 dehydrogenase inhibition. However, one should note that cytosolic ALDH activity was also inhibited upon in vivo treatment with GTN ( $60.8 \pm 4.5 \mu\text{M}$  in control cytosol versus  $23.1 \pm 0.5 \mu\text{M}$  in cytosol from tolerant animals,  $n = 3$ ;  $\text{MV} \pm \text{S.E.M.}$ ).

**Inhibition of ALDH-2 Dehydrogenase Activity by Sin-1-Derived Peroxynitrite.** To demonstrate the sensitivity of ALDH-2 dehydrogenase activity toward oxidative inactivation, we assessed the effect of the peroxynitrite generator

Sin-1 on ALDH-2 activity. Sin-1 releases peroxynitrite constantly over a time period of 90 min (at pH 7.4 and 37°C) to generate low steady-state concentrations of peroxynitrite (Daiber et al., 2002). In mitochondria from control animals, the presence of Sin-1 (1 mM) caused a 60% loss of ALDH-2 activity ( $15.7 \pm 2.1$  versus  $6.1 \pm 1.1 \mu\text{M}$  benzoic acid/30 min,  $n = 3$ ;  $\text{MV} \pm \text{S.E.M.}$ ). Sin-1 at a concentration of 100  $\mu\text{M}$  still caused 30% inhibition of ALDH-2 ( $15.7 \pm 2.1$  versus  $9.8 \pm 1.7 \mu\text{M}$  benzoic acid/30 min,  $n = 3$ ;  $\text{MV} \pm \text{S.E.M.}$ ). The Sin-1 (1 mM)-dependent decrease in ALDH-2 activity was partially prevented in the presence of PEG-SOD (500 U/ml,  $6.1 \pm 1.1$  versus  $10.4 \pm 0.8 \mu\text{M}$  benzoic acid/30 min,  $n = 3$ ;  $\text{MV} \pm \text{S.E.M.}$ ) and completely prevented by the addition of DTT (1 mM,  $6.1 \pm 1.1$  versus  $14.8 \pm 1.1 \mu\text{M}$  benzoic acid/30 min,  $n = 3$ ;  $\text{MV} \pm \text{S.E.M.}$ ). DTT (1 mM) was also able to restore ALDH-2 activity in isolated mitochondria from in vivo GTN-treated, tolerant animals ( $10.1 \pm 1.2$  versus  $17.1 \pm 1.1 \mu\text{M}$  benzoic acid/30 min,  $n = 3$ ;  $\text{MV} \pm \text{S.E.M.}$ ) to the level of control.

**Inhibition of ALDH-2 Esterase Activity by Organic Nitrates.** Esterase activity in isolated rat heart mitochondria was measured by the conversion of methylbenzoate to benzoic acid. Because several esterases are present in mitochondria, special precautions had to be taken to specifically determine the contribution of ALDH-2 to total esterase activity. The horizontal line 1 in Fig. 5A (right axis) defines the level of total esterase activity in control mitochondria, whereas line 2 defines the oxidation-resistant esterase activity. The esterase activity of ALDH-2 involves redox-sensitive sulfhydryl groups and should be inhibited by oxidants (Senior and Tsai, 1990; Tsai and Senior, 1991). Therefore, this activity is represented by the difference between lines 1 and 2. ALDH-2 esterase activity was almost completely inhibited by thiol-oxidants such as peroxynitrite (500  $\mu\text{M}$ ) and hydrogen peroxide (10 mM; Fig. 5A). It is interesting that GTN




**Fig. 3.** Formation of mitochondrial ROS and inhibition of ALDH-2 dehydrogenase activity in response to different organic nitrates. A, formation of mitochondrial ROS detected using L-012 (100  $\mu\text{M}$ )-derived chemiluminescence in mitochondria isolated from rat hearts. Mitochondrial suspensions (0.2 mg/ml final protein) were treated with different organic nitrates (50–5000  $\mu\text{M}$ ). The measurements were initiated by adding succinate (4 mM). The data are the mean  $\pm$  S.E.M. of 3 to 5 independent experiments. B, inhibition of ALDH-2 determined by HPLC-based measurements of the conversion of benzaldehyde to benzoic acid. Suspensions of rat heart mitochondria (1 mg/ml final protein) were treated with different nitrates (50–5000  $\mu\text{M}$ ). The data are the mean  $\pm$  S.E.M. of 3 to 6 independent experiments. \*, significance versus control.

applied in vitro and in vivo also inhibited ALDH-2 esterase activity to a comparable extent (Fig. 5A). In contrast, PETN, ISDN, and ISMN did not significantly affect esterase activity (Fig. 5A). The mixed disulfide-forming reagent DTNB caused complete inhibition of total esterase activity, whereas the ALDH inhibitors benomyl (1  $\mu\text{M}$ ) and chloral hydrate (10  $\mu\text{M}$ ) inhibited only the oxidant-sensitive esterase activity (Fig. 5B), supporting the conclusion that ALDH-2 esterase activity accounts for the oxidant-sensitive esterase. PETN and its metabolites did not alter esterase activity (Fig. 5B).

**Effect of ALDH-2 Inhibition on GTN Biotransformation in RAW 264.7 Macrophages.** According to a previous study (Chen et al., 2002), RAW 264.7 macrophages contain appreciable amounts of ALDH-2. To confirm that ALDH-2 accounts for GTN biotransformation, we measured the formation of 1,2- and 1,3-GDN from GTN by these macrophages by means of GC-MS analysis. As shown in Fig. 6, the ratio of 1,2-GDN/1,3-GDN increased 4-fold with decreasing GTN concentrations (from 10 to 1  $\mu\text{M}$ ). This finding indicates that the pattern of biotransformation is highly sensitive to the GTN concentration used and is in accordance with a substrate-based inactivation of ALDH-2 by excess GTN. Experiments with the ALDH-2 inhibitors benomyl and daidzin (50  $\mu\text{M}$  each) were performed in the presence of 1  $\mu\text{M}$  GTN. Both inhibitors significantly decreased the 1,2-GDN/1,3-GDN ratio to approximately 1 (Fig. 6).

## Discussion

We (Sydow et al., 2004) and others (Chen et al., 2002) have shown that ALDH-2 significantly biotransforms GTN in vitro



**Fig. 4.** Formation of mitochondrial ROS and inhibition of ALDH-2 dehydrogenase activity in response to PETN and its metabolites. A, formation of mitochondrial ROS detected using L-012 (100  $\mu\text{M}$ )-derived chemiluminescence in mitochondria isolated from rat hearts. Mitochondrial suspensions (0.2 mg/ml final protein) were treated with PETN or its metabolites PETriN, PEDN, and PEMN (500  $\mu\text{M}$  each). The measurements were initiated by adding succinate (4 mM). The data are the mean  $\pm$  S.E.M. of 7 to 10 independent experiments. B, inhibition of ALDH-2 determined by HPLC-based measurements of the conversion of benzaldehyde to benzoic acid. Suspensions of rat heart mitochondria (1 mg/ml final protein) were treated with PETN or its metabolites (each 500  $\mu\text{M}$ ). The data are the mean  $\pm$  S.E.M. of 5 to 11 independent experiments. \*, significance versus control.

and in vivo and that inhibition of this enzyme markedly decreased the vasodilator potency of GTN. In the present study, we sought to determine whether ALDH-2 is also required for the bioactivation of other commonly used organic nitrates.

We now show that ALDH-2 inhibition by benomyl decreases the vasodilator potency of PETN and PETriN in rat aorta but not that of ISDN, PEDN, ISMN, and PEMN (Fig. 1, Table 1). These findings were corroborated by our observation that only GTN- and PETN-induced activation of both cGK-I (assessed by P-VASP formation) and sGC (assessed by cGMP formation) were decreased by ALDH-2 inhibitors, whereas activation of these enzymes by the other organic nitrates were not affected by ALDH-2 inhibition (Fig. 2, A and B). Moreover, we show that GTN, PETN, and PETriN exhibit the highest potency to induce mitochondrial ROS formation (Figs. 3A and 4A) and inhibit ALDH-2 dehydrogenase activity (Figs. 3B and 4B). In general, the vasodilator potency, dependence on ALDH-2-catalyzed bioactivation, stimulation of mitochondrial ROS, and inhibition of ALDH-2 dehydrogenase activity increase with the number of  $-\text{ONO}_2$  groups present in the organic nitrate molecule. A remarkable deviation from this general behavior was the finding that PETN and PETriN did not inhibit ALDH-2 esterase activity, whereas GTN did (Fig. 5).


**The Requirement of ALDH-2 for cGMP-Dependent Vasodilator Activity of Organic Nitrates Is Confined to Nitrates with High Vasodilator Potency.** The vasodilator potency of the different organic nitrates tested here roughly correlated with the number of nitrate groups present in the molecule. It decreased in the order PETN > GTN > PETriN > ISDN > PEDN > ISMN > PEMN (Table 1). This order is in accordance with previous studies in the same and in other vessel types (Parker et al., 1975). ALDH-2 inhibition by benomyl specifically affected the vasodilator responses to GTN, PETN, and PETriN, but not to mono- and dinitrates (Table 1), indicating a specific interference with bioactivation of higher-nitrated organic nitrates. Benomyl did not influence ACh-induced relaxations; i.e., it did not interfere with the endothelium-derived NO signaling pathway. In nitrate-tolerant vessels, benomyl was unable to further decrease vasodilator responses to GTN (Sydow et al., 2004) (Table 1), suggesting that both benomyl and nitrate tolerance interfere with the same bioactivation step specifically required for GTN/PETN/PETriN. The results obtained by vasorelaxation experiments were corroborated by the measurement of cGK-I and sGC activation. GTN- and PETN-dependent activation of cGK-I and sGC, which resulted in increased levels of P-VASP and cGMP, respectively, could be suppressed to control levels by benomyl (Fig. 2). In contrast, VASP phosphorylation and cGMP formation induced by all other organic nitrates showed no significant alteration upon the addition of benomyl. Moreover, neither basal nor ACh- or SNP-stimulated P-VASP levels were affected by benomyl, thereby excluding an unspecific impairment of NO/cGMP signaling by this compound.

**Two Independent Pathways Accounting for Vasodilator Activity of Organic Nitrates.** In many vascular beds, the vasodilator-response curve to GTN consists of a high- and a low-potency component (Ahlner et al., 1986), suggesting that bioactivation may not be uniform for a given nitrate and between different nitrates. Superoxide-generating sGC inhibitors such as LY83583 (6-anilino-5,8-quinol-


linedione) and methylene blue (Malta, 1989), as well as the  $G_i$ -inhibitory pertussis toxin (Ahlner et al., 1988), primarily abolish the high-potency component, which can be overcome by higher concentrations of GTN. In contrast, the much less potent ISDN and ISMN exhibit a monophasic dose-response curve. Our previous (Sydow et al., 2004) and present findings showing that the maximal relaxation to GTN, PETN, and PETriN is not affected by benomyl supports the hypothesis of at least two pathways of bioactivation for these organic nitrates. The high-potency pathway may now be identified as the ALDH-2-dependent bioactivation step.

**Organic Nitrate-Induced Oxidative Stress and Inhibition of ALDH-2 Dehydrogenase and Esterase Activity.** Oxidative stress plays an important role in the development of nitrate tolerance and cross-tolerance (Hink et al., 2003). Superoxide and peroxynitrite were identified as the

reactive species formed in tolerant vessels, and peroxynitrite scavengers such as uric acid and ebselen normalized endothelial dysfunction in tolerant vessels. Here we present evidence that at least a part of the organic nitrate-induced oxidative stress may originate from mitochondrial nitrate metabolism. Using L-012-dependent chemiluminescence (Daiber et al., 2004), we detected peroxynitrite and superoxide in isolated rat heart mitochondria upon *in vitro* administration of organic nitrates. It is interesting that the potency of organic nitrates to generate mitochondrial superoxide and peroxynitrite, as well as to inhibit ALDH-2 dehydrogenase activity, increased with their vasodilator potency. This is not contradictory, because ALDH-2 contains three cysteine residues in the catalytic center (Fig. 7), rendering the dehydrogenase activity highly sensitive toward oxidative inactivation (Senior and Tsai, 1990; Tsai and Senior, 1991). In addition to




**Fig. 5.** Effects of organic nitrates, ALDH inhibitors, and ROS on ALDH-2 esterase activity. A, activity of ALDH-2 determined by HPLC-based measurements of the conversion of methylbenzoate to benzoic acid and methanol. Suspensions of rat heart mitochondria (1 mg/ml final protein) were pretreated with authentic peroxynitrite (PN), GTN, PETN, ISDN, ISMN (500  $\mu$ M each), or hydrogen peroxide ( $H_2O_2$ , 10 mM). For comparison, mitochondria from *in vivo* GTN-treated, nitrate-tolerant rats were used. Line 1 indicates the level of total mitochondrial esterase activity in a control sample. The space between line 1 and 2 indicates the part of total mitochondrial esterase activity that can be inhibited by ROS. The data are the mean  $\pm$  S.E.M. of 3 to 4 independent experiments. B, suspensions of rat heart mitochondria (0.5 mg/ml final protein) treated with Ellman's reagent (DTNB, 5 mM), PETN, PETriN, PEDN, PEMN (500  $\mu$ M each), or the ALDH inhibitors benomyl (Beno, 1  $\mu$ M) and chloral hydrate (Chloral, 10  $\mu$ M). Line 1 indicates the level of total mitochondrial esterase activity in a control sample. The space between line 1 and 2 indicates the part of total mitochondrial esterase activity that is sensitive to ALDH inhibitors. The data are the mean  $\pm$  S.E.M. of 3 to 5 independent experiments. \*, significance versus control.




**Fig. 6.** Effect of ALDH-2 inhibition on GTN biotransformation (1,2-GDN/1,3-GDN ratio) in RAW 264.7 macrophages. Cells ( $50 \times 10^6$ ) were incubated with GTN (1–10  $\mu$ M). The GTN metabolites were measured by GC-MS [see insert for a typical chromatogram of injected standards (10  $\mu$ M each)]. The biotransformation of 1  $\mu$ M GTN was also determined in the presence of the ALDH-2 inhibitors benomyl (50  $\mu$ M) or daidzin (50  $\mu$ M). The data are the mean  $\pm$  S.E.M. of 3 to 6 independent experiments. \*, significance versus GTN (10  $\mu$ M)-treated sample; #, significance versus GTN (1  $\mu$ M)-treated sample.



its dehydrogenase activity, ALDH-2 also exhibits esterase activity (Scheme 1), which has been proposed to be essential for the bioactivation of GTN (Chen et al., 2002). This activity also involves oxidation-sensitive cysteine residues that are different from the dehydrogenase activity (Tsai and Senior, 1991). As depicted in Scheme 2, the bioactivation of GTN by ALDH-2 could lead to oxidative inactivation of the enzyme, presumably by the formation of disulfide and/or sulfenic and sulfinic acid. Indeed, 30 to 40% of total (DTNB-sensitive) mitochondrial esterase activity was sensitive to inhibition by



**Fig. 7.** Crystal structure of bovine mitochondrial ALDH. The structure was rendered from the protein database file 1A4Z.pdb using the freeware program PyMol Molecular Graphics System (version 0.93) from DeLano Scientific L.L.C. (San Carlos, CA). The structure shows one monomer of the active tetramer complex. The active site contains three cysteine thiol groups (Cys301–303). One of these thiol groups (most recently from Cys301) is near the nicotinamide ring of the cofactor  $\text{NAD}^+$  and probably participates in the catalytic hydride transfer from an aldehyde to the cofactor. Moreover, these three cysteines provide optimal conditions for an oxidation-based inactivation of the enzyme (e.g., by formation of disulfide).



**Scheme 1.** ALDH-2 possesses two different enzymatic activities. The dehydrogenase activity catalyzes the conversion of aldehydes to carboxylic acids using  $\text{NAD}^+$  as a cofactor. In the present study, this activity was measured by HPLC-based analysis of the conversion of benzaldehyde to benzoic acid. The esterase activity catalyzes the hydrolysis of esters to the free acid and an alcohol without requiring a cofactor. In the present study, this activity was measured by HPLC-based analysis of the hydrolysis of methylbenzoate to benzoic acid and methanol.

**Scheme 2.** GTN biotransformation by ALDH-2. GTN bioactivation has been postulated to essentially involve the ALDH-2 esterase activity yielding 1,2-GDN and nitrite, which is further bioactivated to vasodilating species. This reaction is not a simple ester hydrolysis but also involves the reduction of the  $-\text{ONO}_2$  group to nitrite and alcohol. Although the reaction has a reductive character,  $\text{NAD}^+$  accelerates the catalytic cycle, indicating that steric aspects may play a role. During the catalytic cycle, the enzyme is inactivated as envisaged by the formation of a disulfide bridge. The activity can partially be restored by DTT but not via administration of glutathione (GSH) or cysteine (Cys).

oxidants such as peroxyxynitrite and hydrogen peroxide and inhibited to a similar extent by benomyl and chloral hydrate. Therefore, this part of ALDH-2 esterase activity is expected to be essential for the bioactivation of GTN and PETN and impaired by nitrate tolerance. Indeed, we could demonstrate that GTN *in vivo* and *in vitro* treatment inhibited the mitochondrial esterase activity to a similar extent. In contrast, all other nitrates did not affect esterase activity. In accordance with the oxidative stress concept, previous reports have shown that antioxidants such as ascorbic acid positively influence the development of nitrate tolerance (Daniel and Nawarskas, 2000; Schwemmer and Bassenge, 2003) and that oxidatively inactivated ALDH-2 activity can be restored by the addition of DTT (Chen et al., 2002; Sydow et al., 2004).

Another characteristic feature of the high-potency bioactivation pathway is the rapid desensitization (tachyphylaxis) by GTN concentrations  $>1 \mu\text{M}$  (Chen et al., 2002). At the molecular level, tachyphylaxis can now be related to autoinhibition of GTN bioactivation by mitochondrial ALDH-2, because in RAW 264.7 macrophages GTN concentrations  $>1 \mu\text{M}$  decreased the formation of 1,2-GDN, which is associated with vasorelaxation and sGC activation (Brien et al., 1988). Furthermore, the formation of the 1,2-GDN metabolite was inhibited by the ALDH inhibitors benomyl and daidzin (Fig. 6).

**Comparison of GTN versus PETN and PETriN.** Although the highly potent nitrates share a common bioactivation pathway, we noted some remarkable differences between GTN and PETN/PETriN. First, PETN and PETriN elicited significantly less mitochondrial superoxide formation at similar concentrations compared with GTN. Second, PETN and PETriN caused less inactivation of ALDH-2 dehydrogenase activity compared with GTN. Moreover, in contrast to GTN, both PETN and PETriN did not inhibit mitochondrial esterase activity. These results may explain the previous findings that PETN lacks not only *in vivo* tolerance (Mullenheim et al., 2001; Schwemmer and Bassenge, 2003),

but also, as shown here, in vitro tolerance. In contrast, PETN bioactivity was reduced by cross-tolerance after treatment with GTN in vivo and in vitro, indicating that both nitrates share a common bioactivation pathway. In addition, preliminary results of an in vivo PETN study demonstrate that high-dose PETN in vivo treatment neither causes significant tolerance versus PETN-dependent relaxation nor significant cross-tolerance versus GTN-dependent relaxation (M. Coldewey, A. Daiber, A. Seeling, D. Stalleicken, J. Lehmann, A. Mülsch, and T. Münzel, unpublished observations) (data not shown).

**Mechanism of sGC Activation by Organic Nitrates.** The present ALDH-2 concept does not provide the molecular link between mitochondrial nitrite formation and sGC activation leading to vasorelaxation (see Scheme 2). Nitrite may activate sGC via intermediate formation of  $\text{HNO}_2$  and disproportionation into  $\text{NO}_2$  and  $\text{NO}$ . However, because of the low  $pK$  of  $\text{HNO}_2$ , this requires at least 1000-fold higher concentrations of nitrite at physiological intracellular pH than provided by vasorelaxing concentrations of GTN, or a pH around 4. Indeed, we could not detect the release of  $\text{NO}$  from isolated blood vessels during GTN ( $<1 \mu\text{M}$ )-induced relaxation (Kleschyov et al., 2003). Therefore, free diffusible  $\text{NO}$  may not account for sGC activation by low concentrations of GTN. Nevertheless, we may not completely rule out the possibility that our  $\text{NO}$  EPR detection approach fails to detect minute amounts of  $\text{NO}$  generated from GTN and PETN within discrete intracellular compartments (e.g., mitochondria). However, even with this possibility admitted, our hypothesis of the existence of two different bioactivation mechanisms accounting for organic nitrates with high and low vasodilator potency is not disproved. Moreover, our observations result in another attractive hypothesis: that the vasodilator potency of organic nitrates correlates with their ability to induce mitochondrial reactive oxygen and nitrogen species formation (such as peroxynitrite). At low steady-state concentrations, peroxynitrite has been reported to cause vasodilation (Villa et al., 1994). This implies that GTN- and PETN-dependent relaxation at concentrations  $<1 \mu\text{M}$  may be induced by mitochondrial peroxynitrite formation.

In contrast, sGC activation by higher concentrations of nitrates seems to be mediated by free  $\text{NO}$ , because we could detect the GTN- and ISDN-derived  $\text{NO}$  at concentrations exceeding  $10 \mu\text{M}$ . This ALDH-2-independent pathway is apparently shared by the other low-potency organic nitrates. Benomyl no longer consistently inhibits vasorelaxation at these high concentrations of GTN.

In summary, we provide further evidence for the hypothesis that at least two different pathways exist for the bioactivation of organic nitrates (Ahlner et al., 1986; Kleschyov et al., 2003): The high-affinity pathway metabolizes organic nitrates with high vasorelaxant potency (GTN, PETN, and PETriN), depends on ALDH-2 esterase activity, and is only operative in the submicromolar concentration range; it does not generate measurable quantities of free nitric oxide and is subject to tachyphylaxis and tolerance by either long-lasting in vivo exposure to low concentrations of these organic nitrates or short-term in vitro exposure to concentrations exceeding  $1 \mu\text{M}$  GTN. The low-affinity pathway is operative at higher concentrations of the highly potent organic nitrates and for the organic nitrates with lower vasorelaxant potency (ISDN, ISMN, PEDN, and PEMN). This pathway is indepen-

dent of ALDH-2, yields measurable quantities of free  $\text{NO}$ , and is less prone to tolerance development.

#### Acknowledgments

The expert technical assistance of Claudia Kuper, Hartwig Wieboldt, and Gudrun Junge is gratefully acknowledged.

#### References

- Abrams J (1987) Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration. *Drugs* **34**:391–403.
- Abrams J (1995) The role of nitrates in coronary heart disease. *Arch Intern Med* **155**:357–364.
- Ahlner J, Axelsson KL, Ekstram-Ljusegren M, Friedman RL, Grundstrom N, Karlsson JO, and Andersson RG (1988) Relaxation of bovine mesenteric artery induced by glyceryl trinitrate is attenuated by pertussis toxin. *Pharmacol Toxicol* **62**:155–158.
- Ahlner J, Axelsson KL, Ljusegren ME, Grundstrom N, and Andersson RG (1986) Demonstration of a high affinity component of glyceryl trinitrate induced vasodilatation in the bovine mesenteric artery. *J Cyclic Nucleotide Protein Phosphor Res* **11**:445–456.
- Brien JF, McLaughlin BE, Kobus SM, Kawamoto JH, Nakatsu K, and Marks GS (1988) Mechanism of glyceryl trinitrate-induced vasodilation. I. Relationship between drug biotransformation, tissue cyclic GMP elevation and relaxation of rabbit aorta. *J Pharmacol Exp Ther* **244**:322–327.
- Brune B and Ullrich V (1987) Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. *Mol Pharmacol* **32**:497–504.
- Chen Z, Zhang J, and Stamler JS (2002) Identification of the enzymatic mechanism of nitroglycerin bioactivation. *Proc Natl Acad Sci USA* **99**:8306–8311.
- Daiber A, Frein D, Namgaladze D, and Ullrich V (2002) Oxidation and nitrosation in the nitrogen monoxide/superoxide system. *J Biol Chem* **277**:11882–11888.
- Daiber A, Oelze M, August M, Wendt M, Sydow K, Wieboldt H, Kleschyov AL, and Munzel T (2004) Detection of superoxide and peroxynitrite in model systems and mitochondria by the luminol analogue L-012. *Free Radic Res* **38**:259–269.
- Daniel TA and Nawarskas JJ (2000) Vitamin C in the prevention of nitrate tolerance. *Ann Pharmacother* **34**:1193–1197.
- DiFabio J, Ji Y, Vasiliou V, Thatcher GR, and Bennett BM (2003) Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. *Mol Pharmacol* **64**:1109–1116.
- Eigenthaler M, Ullrich H, Geiger J, Horstrup K, Honig-Liedl P, Wiebecke D, and Walter U (1993) Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. *J Biol Chem* **268**:13526–13531.
- Fink B and Bassenge E (1997) Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythritol tetranitrate. *J Cardiovasc Pharmacol* **30**:831–836.
- Gerardin A, Gaudry D, and Wantiez D (1982) Gas chromatographic mass spectrometric determination of 1,2,3-propanetrioltrinitrate (nitroglycerin) in human plasma using the nitrogen-15 labelled compound as internal standard. *Biomed Mass Spectrom* **9**:333–335.
- Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, Mollnau H, August M, Baldus S, Tseliminas N, et al. (2003) Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. *J Am Coll Cardiol* **42**:1826–1834.
- Ignarro LJ (2002) Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. *J Physiol Pharmacol* **53**:503–514.
- Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, and Parker JD (2001) Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. *J Am Coll Cardiol* **38**:854–859.
- Kleschyov AL, Oelze M, Daiber A, Huang Y, Mollnau H, Schulz E, Sydow K, Fichtlscherer B, Mülsch A, and Munzel T (2003) Does nitric oxide mediate the vasodilator activity of nitroglycerin? *Circ Res* **93**:e104–e112.
- Lau DT, Chan EK, and Benet LZ (1992) Glutathione S-transferase-mediated metabolism of glyceryl trinitrate in subcellular fractions of bovine coronary arteries. *Pharm Res (NY)* **9**:1460–1464.
- Malta E (1989) Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings. Evidence for two mechanisms of action. *Naunyn-Schmiedeberg's Arch Pharmacol* **339**:236–243.
- Mangione NJ and Glasser SP (1994) Phenomenon of nitrate tolerance. *Am Heart J* **128**:137–146.
- McDonald LJ and Murad F (1995) Nitric oxide and cGMP signaling. *Adv Pharmacol* **34**:263–275.
- Mullenheim J, Muller S, Laber U, Thamer V, Meyer W, Bassenge E, Fink B, and Kojda G (2001) The effect of high-dose pentaerythritol tetranitrate on the development of nitrate tolerance in rabbits. *Naunyn-Schmiedeberg's Arch Pharmacol* **364**:269–275.
- Mülsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, Walter U, Stasch JP, Warnholtz A, Hink U, et al. (2001) Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. *Circulation* **103**:2188–2194.
- Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, Oelze M, Skatchkov M, Warnholtz A, Duncker L, et al. (2000) Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production and vascular NO bioavailability. *Circ Res* **86**:E7–E12.
- Munzel T, Sayegh H, Freeman BA, Tarpey MM, and Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. *J Clin Invest* **95**:187–194.
- Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA, Schneider HT,

- Stalleicken D, and Schroder H (2003) Endothelial protection by pentaerythrityl trinitrate: bilirubin and carbon monoxide as possible mediators. *Exp Biol Med (Maywood)* **228**:529–534.
- Oberle S, Schwartz P, Abate A, and Schroder H (1999) The antioxidant defense protein ferritin is a novel and specific target for pentaerythrityl tetranitrate in endothelial cells. *Biochem Biophys Res Commun* **261**:28–34.
- O'Byrne S, Shirodaria C, Millar T, Stevens C, Blake D, and Benjamin N (2000) Inhibition of platelet aggregation with glyceryl trinitrate and xanthine oxidoreductase. *J Pharmacol Exp Ther* **292**:326–330.
- Parker JC, Di Carlo FJ, and Davidson IW (1975) Comparative vasodilator effects of nitroglycerin, pentaerythritol trinitrate and biometabolites and other organic nitrates. *Eur J Pharmacol* **31**:29–37.
- Pfaffenrath V, de la Motte S, Harrison F and Ruthning C (1998) Actions of pentaerythritol tetranitrate, isosorbide mononitrate and placebo on headache and ability to work of healthy subjects. *Arzneimittelforschung* **48**:646–650.
- Raha S, McEachern GE, Myint AT, and Robinson BH (2000) Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. *Free Radic Biol Med* **29**:170–180.
- Saha A, Goldstein S, Cabelli D, and Czapski G (1998) Determination of optimal conditions for synthesis of peroxynitrite by mixing acidified hydrogen peroxide with nitrite. *Free Radic Biol Med* **24**:653–659.
- Schroder H (1992) Cytochrome P-450 mediates bioactivation of organic nitrates. *J Pharmacol Exp Ther* **262**:298–302.
- Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmuller S, Walter U, Reichenspurner H, Meinertz T, et al. (2002) Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. *Circulation* **105**:1170–1175.
- Schwemmer M and Bassenge E (2003) New approaches to overcome tolerance to nitrates. *Cardiovasc Drugs Ther* **17**:159–173.
- Senior DJ and Tsai CS (1990) Esterase activity of high-Km aldehyde dehydrogenase from rat liver mitochondria. *Biochem Cell Biol* **68**:758–763.
- Sladek NE (2003) Human aldehyde dehydrogenases: potential pathological, pharmacological and toxicological impact. *J Biochem Mol Toxicol* **17**:7–23.
- Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mulsch A, Schulz E, Kearney JF Jr, et al. (2004) Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. *J Clin Invest* **113**:482–489.
- Tsai CS and Senior DJ (1991) Chemical studies of high-Km aldehyde dehydrogenase from rat liver mitochondria. *Biochem Cell Biol* **69**:193–197.
- Villa LM, Salas E, Darley-Usmar VM, Radomski MW, and Moncada S (1994) Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. *Proc Natl Acad Sci USA* **91**:12383–12387.
- Warnholtz A, Tsilimingas N, Wendt M, and Munzel T (2002) Mechanisms underlying nitrate-induced endothelial dysfunction: insight from experimental and clinical studies. *Heart Fail Rev* **7**:335–345.
- Yamaguchi T, Terakado M, Horio F, Aoki K, Tanaka M, and Nakajima H (1996) Role of bilirubin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase. *Biochem Biophys Res Commun* **223**:129–135.

---

**Address correspondence to:** Dr. Andreas Daiber, Universitätsklinikum Eppendorf, Medizinische Klinik III – Labor für Experimentelle Kardiologie, Martinistr. 52, 20246 Hamburg, Germany. E-mail: andreas.daiber@bioredox.com

---